ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021
PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02624518 (68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Detection of Biochemically Recurrent Prostate Cancer with [Tomography (Ann Arbor, Mich.) · 2023Pooled it
- Diagnostic accuracy of fully hybrid [European journal of nuclear medicine and molecular imaging · 2024Trial
- Design, Synthesis, and Preclinical Evaluation of Novel Dimeric RM2-Based Radioligands for GRPR-Targeted Breast Cancer Imaging.Molecular pharmaceutics · 2026Article
- GRPR-Targeted Radionuclide Conjugates: A Molecular Evolution Perspective.Chemistry & biodiversity · 2026Review
- PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making.Cancers · 2026Review
- Diagnostic performance of gastrin-releasing peptide receptor-targeted positron-emission tomography in biochemically recurrent prostate cancer-a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2026Article
- The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025Review
- Phase I Clinical Study with the GRPR-Antagonist [Pharmaceutics · 2025Article
- Nanomaterials for Theranostic Management of Oral Cancer: Advances in Imaging, Biosensing, Targeted Delivery, and Multimodal Synergistic Therapy.International journal of nanomedicine · 2025Review
- Evaluation of a tumor marker gastrin-releasing peptide precursor in the patients with kidney injuries.American journal of cancer research · 2025Article
- Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer.Annals of medicine · 2024Review
- Update on PSMA-based Prostate Cancer Imaging.Seminars in nuclear medicine · 2024Review
- Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study.Pharmaceutics · 2024Article
- Synthesis and Evaluation of the FirstMolecules (Basel, Switzerland) · 2024Article
- The Diagnostic Performance ofIranian journal of public health · 2024Review
- Synthesis and Evaluation of NovelPharmaceuticals (Basel, Switzerland) · 2024Article
- GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics.Pharmaceutics · 2024Article
- Unnatural amino acid substitutions to improve in vivo stability and tumor uptake ofEJNMMI radiopharmacy and chemistry · 2024Article
- The Balance Between the Therapeutic Efficacy and Safety of [Molecular imaging and biology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel radiopharmaceuticals for PET are being evaluated for the diagnosis of biochemical recurrence (BCR) of prostate cancer (PC). We compared the gastrin-releasing peptide receptor-targeting
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.